MX2022011472A - Formato de anticuerpo multiespecifico heterodimerico. - Google Patents

Formato de anticuerpo multiespecifico heterodimerico.

Info

Publication number
MX2022011472A
MX2022011472A MX2022011472A MX2022011472A MX2022011472A MX 2022011472 A MX2022011472 A MX 2022011472A MX 2022011472 A MX2022011472 A MX 2022011472A MX 2022011472 A MX2022011472 A MX 2022011472A MX 2022011472 A MX2022011472 A MX 2022011472A
Authority
MX
Mexico
Prior art keywords
hetero
specific antibody
antibody format
domains
dimeric multi
Prior art date
Application number
MX2022011472A
Other languages
English (en)
Inventor
David Urech
Sebastian Meyer
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of MX2022011472A publication Critical patent/MX2022011472A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a nuevo formato multiespecífico heterodimérico de múltiples dominios variables de anticuerpos que comprenden un núcleo de dos pares de dominios variables divididos en el que tanto los dominios ligeros variables como los dos dominios pesados variables afines están situados en tándem en dos cadenas proteicas separadas, respectivamente.
MX2022011472A 2015-06-15 2017-12-13 Formato de anticuerpo multiespecifico heterodimerico. MX2022011472A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15001758 2015-06-15

Publications (1)

Publication Number Publication Date
MX2022011472A true MX2022011472A (es) 2023-03-01

Family

ID=53434175

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017016188A MX2017016188A (es) 2015-06-15 2016-06-15 FORMATO DE ANTICUERPO MULTIESPECíFICO HETERODIMí‰RICO.
MX2022011472A MX2022011472A (es) 2015-06-15 2017-12-13 Formato de anticuerpo multiespecifico heterodimerico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017016188A MX2017016188A (es) 2015-06-15 2016-06-15 FORMATO DE ANTICUERPO MULTIESPECíFICO HETERODIMí‰RICO.

Country Status (13)

Country Link
US (2) US11236150B2 (es)
EP (2) EP3307776A1 (es)
JP (3) JP6839101B2 (es)
KR (1) KR20180012860A (es)
CN (2) CN107922486B (es)
AU (2) AU2016278586B2 (es)
CA (1) CA2989474C (es)
EA (1) EA201890041A1 (es)
HK (1) HK1245805A1 (es)
IL (2) IL293435A (es)
MA (1) MA44381A (es)
MX (2) MX2017016188A (es)
WO (1) WO2016202457A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
MA49249A (fr) 2017-06-05 2021-04-14 Numab Therapeutics AG Nouveaux anticorps anti-hsa
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
SG11201911527QA (en) * 2017-06-05 2020-01-30 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
EP3470428A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting cd137 and methods of use thereof
SG11202003111SA (en) 2017-10-10 2020-05-28 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
EP3694879A1 (en) 2017-10-10 2020-08-19 Numab Therapeutics AG Antibodies targeting pdl1 and methods of use thereof
EP3470429A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
CN111194323B (zh) 2017-10-10 2024-07-09 努玛治疗有限公司 多特异性抗体
WO2019136405A1 (en) * 2018-01-05 2019-07-11 City Of Hope Multi-specific ligand binders
EP3636320A1 (en) 2018-10-09 2020-04-15 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
TWI839395B (zh) 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
CN113631574A (zh) 2019-01-31 2021-11-09 努玛治疗有限公司 对TNFα和IL-17A具有特异性的多特异性抗体、靶向IL-17A的抗体及其使用方法
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
EP3915580A1 (en) 2020-05-29 2021-12-01 Numab Therapeutics AG Multispecific antibody
TWI806087B (zh) * 2020-06-30 2023-06-21 大陸商和鉑醫藥（上海）有限責任公司 免疫細胞銜接多特異性結合蛋白及其製備和應用
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
IL303166A (en) 2020-12-23 2023-07-01 Numab Therapeutics AG Antibody variable domains that bind IL-31
EP4019546A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Antibody variable domains that bind il-31
EP4019090A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Antibody variable domains that bind il-4r
WO2022136693A1 (en) 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
CA3208781A1 (en) 2021-02-02 2022-08-11 Bithi CHATTERJEE Multispecific antibodies having specificity for ror1 and cd3
CN115536749A (zh) 2021-06-29 2022-12-30 三生国健药业（上海）股份有限公司 三特异性抗体、其制备方法和用途
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
EP4273162A1 (en) 2022-05-06 2023-11-08 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2023214047A1 (en) 2022-05-06 2023-11-09 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2276735T3 (es) 2001-09-14 2007-07-01 Affimed Therapeutics Ag Anticuerpos fv multimericos de cadena sencilla en tandem.
WO2004094613A2 (en) * 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
WO2010132872A1 (en) * 2009-05-15 2010-11-18 Novimmune S.A Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
EP2445936A1 (en) 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
GB201000467D0 (en) * 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
TWI588156B (zh) * 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US20150045540A1 (en) * 2011-06-28 2015-02-12 Sea Lane Biotechnologies, Llc Multispecific stacked variable domain binding proteins
WO2014022540A1 (en) * 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
CA2900154A1 (en) * 2013-02-05 2014-08-14 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
RU2015152077A (ru) * 2013-05-07 2017-06-13 Ф.Хоффманн-Ля Рош Аг Тримерные антигенсвязывающие молекулы
WO2014180577A1 (en) 2013-05-10 2014-11-13 Numab Ag Bispecific constructs and their use in the treatment of various diseases
SG10201811017QA (en) 2013-06-26 2019-01-30 Numab Innovation Ag Novel antibody frameworks
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
EP3156417A1 (en) 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies

Also Published As

Publication number Publication date
EP3307776A1 (en) 2018-04-18
EP4047020A1 (en) 2022-08-24
CN115057936A (zh) 2022-09-16
HK1245805A1 (zh) 2018-08-31
AU2022218544A1 (en) 2022-09-15
IL293435A (en) 2022-07-01
US11879005B2 (en) 2024-01-23
WO2016202457A8 (en) 2017-11-30
JP2021087436A (ja) 2021-06-10
WO2016202457A1 (en) 2016-12-22
US20220332797A1 (en) 2022-10-20
JP6839101B2 (ja) 2021-03-03
US11236150B2 (en) 2022-02-01
AU2016278586A1 (en) 2018-01-04
CA2989474C (en) 2023-09-05
JP2018522545A (ja) 2018-08-16
JP2022177097A (ja) 2022-11-30
CN107922486B (zh) 2022-05-31
IL256314A (en) 2018-02-28
EA201890041A1 (ru) 2018-07-31
IL256314B (en) 2022-06-01
KR20180012860A (ko) 2018-02-06
MX2017016188A (es) 2018-07-06
CA2989474A1 (en) 2016-12-22
AU2016278586B2 (en) 2022-05-19
CN107922486A (zh) 2018-04-17
MA44381A (fr) 2019-01-23
US20180355024A1 (en) 2018-12-13
JP7457764B2 (ja) 2024-03-28
JP7140861B2 (ja) 2022-09-21

Similar Documents

Publication Publication Date Title
MX2022011472A (es) Formato de anticuerpo multiespecifico heterodimerico.
CL2019000424A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
EP3461261A4 (en) PROTEINS BINDING TO THE VARIABLE MONOCATERARY FRAGMENT OF CD3
PH12017502180A1 (en) Tau-binding antibodies
EP3258959A4 (en) Antibody therapeutics that bind cd137
EP3416690A4 (en) SPECIFIC APTAMER
DK3142750T3 (da) Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf
PH12017502207A1 (en) Tau-binding antibodies
IL280004A (en) Antibody molecules that bind PD-L1 and CD137
IL254239A0 (en) Modified antibodies that bind to transforming growth factor-beta-1 with high affinity, avidity and specificity
EP3689903A4 (en) FIBRONECTIN B DOMAIN BINDING PROTEIN
EP3807318A4 (en) MULTISPECIFIC ANTIBODY CONSTRUCTS
EP3554535A4 (en) PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
IL254238B (en) ß1 transforming growth factor binding dimers with high affinity, avidity and specificity
EP3368900A4 (en) Sandwich assay for small molecules
NZ731491A (en) Cd83 binding proteins and uses thereof
IL292799A (en) Antibodies against siglec-9
EP3464598A4 (en) APTAMER-BASED ANALYTICAL TESTS
EP3309169A4 (en) Antibody binding specifically to isolated vimentin-derived peptide, or binding fragment of the peptide
EP3660155A4 (en) ANTI-CD147 ANTIBODY
EP3444273A4 (en) ANTIBODY BINDING SPECIFICALLY TO AIMP2-DX2 PROTEIN
EP3243837A4 (en) Bispecific antibody binding to trailr2 and psma
EP3583134A4 (en) NEW MULTI-SPECIFIC BINDING PROTEINS
GB201818283D0 (en) Antibody molecules that bind PD-L1 and CD137
GB201811405D0 (en) Antibody molecules that bind PD-L1 and CD137